Filing Details

Accession Number:
0001213900-22-041491
Form Type:
13D Filing
Publication Date:
2022-07-25 20:00:00
Filed By:
Regencell (bvi) Ltd
Company:
Regencell Bioscience Holdings Ltd
Filing Date:
2022-07-26
SEC Url:
13D Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Regencell (BVI) Limited 10,561,594 0 10,561,594 0 10,561,594 81.2%
Yat-Gai Au 10,561,594 0 10,561,594 0 10,561,594 81.2%
Filing
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 5) 

 

 

 

Regencell Bioscience Holdings Limited

(Name of Issuer)

 

Ordinary Shares, $0.00001 Par Value

(Title of Class of Securities)

 

G7487R100

(CUSIP Number)

 

Yat-Gai Au

11/F First Commercial Building

33-35 Leighton Road

Causeway Bay, Hong Kong

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

 

July 25, 2022

(Date of Event Which Requires Filing of This Statement)

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

CUSIP Number: G7487R100

 

1

NAME OF REPORTING PERSON: Regencell (BVI) Limited

 

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)       ☐

(b)       ☐

3

SEC USE ONLY

 

4

SOURCE OF FUNDS

AF

5

CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

6

CITIZENSHIP OR PLACE OF ORGANIZATION

British Virgin Islands

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
7

SOLE VOTING POWER

10,561,594 Ordinary Shares

8

SHARED VOTING POWER

0

9

SOLE DISPOSITIVE POWER

10,561,594 Ordinary Shares

10

SHARED DISPOSITIVE POWER

0

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

10,561,594 Ordinary Shares

12

CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

81.2%

14

TYPE OF REPORTING PERSON

CO

 

2

 

 

CUSIP Number: G7487R100

 

1

NAME OF REPORTING PERSON: Yat-Gai Au

 

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)       ☐

(b)       ☐

3

SEC USE ONLY

 

4

SOURCE OF FUNDS

PF

5

CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

6

CITIZENSHIP OR PLACE OF ORGANIZATION

Hong Kong Special Administrative Region of the People’s Republic of China (“Hong Kong”)

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
7

SOLE VOTING POWER

10,561,594 Ordinary Shares

8

SHARED VOTING POWER

0

9

SOLE DISPOSITIVE POWER

10,561,594 Ordinary Shares

10

SHARED DISPOSITIVE POWER

0

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

10,561,594 Ordinary Shares

12

CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

81.2%

14

TYPE OF REPORTING PERSON

IN

 

3

 

 

CUSIP Number: G7487R100

 

This Amendment No. 5 to Schedule 13D (this “Amendment No. 5”) amends and supplements the Schedule 13D (the “Schedule 13D”) filed with the Securities and Exchange Commission (the “SEC”) on July 27, 2021 (as amended to date, the “Schedule 13D”) by Mr. Yat-Gai Au, a Hong Kong citizen, and Regencell (BVI) Limited., a limited liability company organized in British Virgin Islands (“Regencell (BVI) Limited,” and together with Mr. Yat-Gai Au, the “Reporting Persons”), with respect to the ordinary shares of Regencell Bioscience Holdings Limited (the “Company” or “Issuer”), with par value $0.00001 per share (the “Ordinary Shares”). Capitalized terms used herein without definition shall have the meaning set forth in the Schedule 13D.

 

Item 3.Source and Amount of Funds or Other Consideration.

 

Item 3 of the Schedule 13D is hereby amended and supplemented by adding the following at the end of Item 3:

 

Between June 7, 2022 and July 25, 2022, Regencell (BVI) Limited acquired a total of another 22,435 Ordinary Shares from open market purchases at an aggregate price of $885,815. Regencell (BVI) Limited used Mr. Yat-Gai Au’s personal funds to effect these purchases of Ordinary Shares.

 

Item 5.Interest in Securities of the Issuer.

 

Item 5 of the Schedule 13D is hereby amended and restated in its entirety with the following:

 

(a)-(b) The responses to Items 7 to 13 of each of the cover page of this Amendment No. 5 for the Reporting Persons are incorporated herein by reference.

 

Percentage is calculated based on the 13,012,866 ordinary shares of the Issuer issued and outstanding as of July 26, 2022, information provided by the Issuer.

 

Mr. Yat-Gai Au is the sole director and sole shareholder of Regencell (BVI) Limited and may be deemed to beneficially own the securities held by Regencell (BVI) Limited.

 

Except as set forth in this Item 5(a) and (b), to the knowledge of the Reporting Persons, none of the persons identified in Item 2 to Schedule 13D beneficially owns any Ordinary Shares of the Issuer.

 

(c) Between June 7, 2022 and July 25, 2022, Regencell (BVI) Limited acquired an aggregate of another 22,435 Ordinary Shares at share prices between $29.2100 and $44.9223 from open market purchases, all of which were purchased during the past sixty (60) days of the date of this Amendment No. 5. Details of the transactions are set forth below. The Reporting Persons undertake to provide, upon request by the staff of the SEC, full information regarding the number of Ordinary Shares purchased at each separate price for these transactions.

 

Date Number of Ordinary
Shares Purchased
Average Daily Price per
Share
June 7, 2022 1,439 $38.2380
June 8, 2022 1,546 $41.1858
June 9, 2022 1,270 $42.6439
June 10, 2022 2,104 $43.9703
June 13, 2022 200 $42.7500
June 14, 2022 700 $44.7771
June 16, 2022 2,052 $44.9223
June 17, 2022 1,428 $44.5158
June 21, 2022 100 $42.4900
June 22, 2022 2,242 $37.2231
June 23, 2022 800 $34.2575
June 24, 2022 1,554 $31.7374

 

4

 

 

CUSIP Number: G7487R100

 

Date Number of Ordinary
Shares Purchased
Average Daily Price per
Share
June 27, 2022 492 $30.2864
June 28,2022 100 $29.2100
June 29, 2022 100 $30.5200
July 6, 2022 150 $37.0000
July 7, 2022 32 $38.0000
July 8, 2022 363 $37.9994
July 11, 2022 100 $38.0000
July 12, 2022 605 $39.5221
July 13, 2022 300 $39.0135
July 14, 2022 2,740 $38.2136
July 15, 2022 200 $38.4100
July 18, 2022 800 $38.2200
July 19, 2022 100 $39.2000
July 20, 2022 400 $37.7000
July 21, 2022 200 $34.9500
July 25, 2022 318 $33.2452

 

 

Except as disclosed in Items 3, 4 and 5 of the Schedule 13D, no transactions in the Ordinary Shares were effected during the past sixty (60) days by the Reporting Persons, or to the knowledge of the Reporting Persons, any persons identified in Item 2 to Schedule 13D.

 

(d) None.

 

(e) Not applicable.

 

5

 

 

SIGNATURES

 

After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

 

Date: July 26, 2022

 

  Regencell (BVI) Limited
     
  By: /s/ Yat-Gai Au
  Name: Yat-Gai Au
  Title: Sole Director
     
  /s/ Yat-Gai Au
  Name: Yat-Gai Au

 

[Signature Page to Schedule 13D/A]